Nerli R B, Gautam S, Ghagane S C, Rai S
Department of Urology, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Nehru Nagar, Belagavi-590010, Karnataka, India.
Department of Respiratory Medicine, JN Medical College, KLE Academy of Higher Education & Research (Deemed-to-be-University), JNMC Campus, Nehru Nagar, Belagavi-590010, Karnataka, India.
Arch Razi Inst. 2024 Oct 31;79(5):1091-1097. doi: 10.32592/ARI.2024.79.5.1091. eCollection 2024 Oct.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The current pandemic has resulted in a significant reallocation of health-care resources, with the recommended treatment strategy advocating for oncology patients was to delay elective procedures. A retrospective analysis was conducted to evaluatethe impact of COVID-19 on patients with renal cell carcinoma (RCC) and the associated treatment protocols. A retrospective review of the inpatient and outpatient records of all patients presenting with renal cell carcinoma during the period from March 2020 to the end of March 2021 was conducted. A total of 26 patients (21 males and 5 females) with a mean age of 55.46±9.44 years were diagnosed with an operable renal mass during the study period. The mean hospitalisation period (15.19±2.28) was found to be longer in patients who required surgical intervention. The delay was attributable to a number of factors, including the necessity for pre-operative testing using RT-PCR, a chest HR-CT, clearance from the chest physician, and preparation. The overall cost of hospitalization increased in these patients compared to the pre-pandemic period due to a number of factors, including prolonged hospitalization, an increased incidence of complications, the necessity for pre-operative testing for SARS-CoV-2, the use of personal protective equipment, and the provision of nursing care. During the same period, three out of eight patients who had metastatic disease with positive RT-PCR were initiated on targeted therapy, while the remaining underwent cytoreductive nephrectomy. The study concludes that patients with RCC seeking treatment during the current pandemic face significant challenges, including delays in treatment, increased hospitalization rates, and a rise in testing, which collectively contribute to elevated treatment costs. It is imperative to conduct a long-term follow-up to ascertain whether these factors have influenced the outcome of the patients in question.
2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起。当前的大流行导致了医疗资源的重大重新分配,针对肿瘤患者的推荐治疗策略是推迟择期手术。进行了一项回顾性分析,以评估COVID-19对肾细胞癌(RCC)患者的影响以及相关治疗方案。对2020年3月至2021年3月底期间所有出现肾细胞癌的患者的住院和门诊记录进行了回顾性审查。在研究期间,共有26例患者(21例男性和5例女性)被诊断为可手术切除的肾肿块,平均年龄为55.46±9.44岁。发现需要手术干预的患者的平均住院时间(15.19±2.28)更长。延迟归因于多种因素,包括使用逆转录聚合酶链反应(RT-PCR)进行术前检测、胸部高分辨率计算机断层扫描(HR-CT)、胸科医生的许可和准备工作。与大流行前时期相比,这些患者的住院总费用有所增加,原因包括住院时间延长、并发症发生率增加、对SARS-CoV-2进行术前检测的必要性、个人防护设备的使用以及护理服务的提供。在同一时期,8例RT-PCR呈阳性的转移性疾病患者中有3例开始接受靶向治疗,其余患者接受了减瘤性肾切除术。该研究得出结论,在当前大流行期间寻求治疗的RCC患者面临重大挑战,包括治疗延迟、住院率增加和检测次数增加,这些因素共同导致治疗成本上升。必须进行长期随访,以确定这些因素是否影响了相关患者的治疗结果。